Merck (MRK) Completes Acquisition of Harpoon Therapeutics Mar 11, 2024 08:15AM
Merck Completes Acquisition of Harpoon Therapeutics, Inc. Mar 11, 2024 08:15AM
Merck (MRK) to Acquire Harpoon Therapeutics (HARP) for $23/sh Cash or $680M Jan 8, 2024 07:34AM
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline Jan 8, 2024 07:30AM
Harpoon Therapeutics Inc. (HARP) Presents HPN217 Interim Phase 1 Data Sep 28, 2023 05:20AM


Sep 28, 2023 03:00AM Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
Sep 15, 2023 07:15AM Harpoon Therapeutics (HARP) Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
Sep 15, 2023 07:15AM Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
Sep 5, 2023 08:00AM Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
Aug 3, 2023 07:30AM Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
Aug 1, 2023 07:30AM Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
Jun 27, 2023 07:30AM Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
Nov 21, 2019 06:19AM Harpoon Therapeutics Inc. (HARP), AbbVie (ABBV) Report Licensing & Option Collaboration to Advance HPN217
Nov 21, 2019 04:00AM Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
Nov 21, 2019 04:00AM Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration